12月21日，2025"人民好医生 金山茶花计划"总结交流在北京举行。现场汇集了肺癌、肝胆肿瘤、胃 癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展， 助力推进癌症防控事业高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了肝胆肿瘤治疗进展。他说，当前肝胆肿瘤 治疗已迈入免疫主导阶段，免疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分 不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出台，进一步推动肝胆 肿瘤诊疗从"经验型"向"循证型"转变。 "得益于精准诊疗的推广、靶向治疗和免疫治疗的应用等，肺癌患者的生存期和生活质量得到了有效延 长和提升。"广东省人民医院首席专家、广东省肺癌研究所名誉所长吴一龙介绍肺癌领域学术科研创新 进展："近年来，SCLC（小细胞肺癌）领域迎来突破性变革，全新的T细胞抗体激活类药物，在SCLC 二线治疗中效果显著，为临床提供了新的治疗范式；在NSCLC（非小细胞肺癌）早中期领域，相关研 究显示纳武利尤单抗联合化疗新辅助治疗能有效提升患者5年生存率，多款创新药物及治疗方案的出 现，推动非小 ...

中国青年报客户端讯（中青报·中青网记者 余冰玥）癌症是危害公众生命健康、制约居民健康水平提升 的重要因素。12月21日，2025"人民好医生·金山茶花计划"总结交流在北京举行。来自肺癌、胃癌、食 管癌、乳腺癌、妇科肿瘤等领域的专家学者共同探讨癌症防控新进展，助力推进癌症防控事业高质量发 展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉介绍，当前，肝胆肿瘤治疗已迈入免疫主导阶 段，免疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分不可切除肿瘤患者创造 了根治机会。2025年，国内外权威指南修订、国内多项专家共识出台，进一步推动肝胆肿瘤诊疗从"经 验型"向"循证型"转变。"未来诊疗需向精准分层、机制协同、全病程管理深化，既要强化高危人群早筛 早诊与科普宣传，优化联合治疗方案，也要鼓励中青年医生投身临床科研创新、紧盯国际前沿。" "得益于精准诊疗的推广、靶向治疗和免疫治疗的应用等，肺癌患者的生存期和生活质量得到了有效延 长和提升。"广东省人民医院首席专家、广东省肺癌研究所名誉所长吴一龙介绍了近年来肺癌领域学术 科研创新进展，在他看来，当前国内研究提供了"中国方案"，"走向全世界还需要迈出更大的 ...

癌症是危害公众生命健康、制约居民健康水平提升的重要因素。12月21日，2025"人民好医生·金山茶花计划"总结交流在北京举行。现场汇集了肺癌、 肝胆肿瘤、胃癌、食管癌、乳腺癌、妇科肿瘤、泌尿肿瘤、淋巴瘤、鼻咽癌等领域专家，共同探讨癌症防控新进展，助力推进癌症防控事业高质量发展。 立足健康需求 共商癌症防治对策 癌症防治是健康中国建设的重要课题，需锚定群众健康需求，破解现实挑战，凝聚多方合力，推进高质量发展。 中国科学院院士、复旦大学附属中山医院名誉院长樊嘉分享了对于肝胆肿瘤治疗的一些观察与思考。他说，当前肝胆肿瘤治疗已迈入免疫主导阶段，免 疫治疗与靶向、介入治疗的协同联动，显著延长了患者生存期，还为部分不可切除肿瘤创造根治机会。2025年，国内外权威指南修订、国内多项专家共识出 台，进一步推动肝胆肿瘤诊疗从"经验型"向"循证型"转变。樊嘉建议，未来诊疗需向精准分层、机制协同、全病程管理深化，直面百姓健康关切，既要强化 高危人群早筛早诊与科普宣传，优化联合治疗方案，也要鼓励中青年医生投身临床科研创新、紧盯国际前沿。随着人才成长与技术进步，我国肝胆肿瘤防治 事业将实现更高质量发展。 目前，肿瘤治疗已迈入精准化、个 ...

日前国家医保局公布的2025年基本医保目录中，新增114种药品，其中肿瘤用药36种，占比达31.58%， 进一步扩大了肿瘤患者的用药选择。 专家预测，2040年以后，癌症十年生存率或可达到95%左右，2050年癌症有望成为可稳定控制的慢性疾 病。 癌症是全球公共卫生挑战。根据世界卫生组织（WHO）数据，2020年，癌症导致1000万人死亡，占总 死亡人数1/6。癌症是全球第二大死因。有研究指出，若无紧急行动和有针对性的资金支持，2050年全 球癌症死亡人数预计超1800万。 中国在肿瘤领域的科研实力，已成为全球抗癌研究的重要力量。这在国际顶级肿瘤学术会议上得到了印 证。比如，在2025年美国临床肿瘤学会（ASCO）年会上，中国学者有73项研究入选口头报告环节，创 亚洲国家纪录。 （原标题：专家：癌症2050年或将成可控制的慢性病） ...

Core Viewpoint - Cancer is a significant global public health challenge, with the WHO reporting 10 million deaths in 2020, accounting for 1/6 of total deaths, and projections indicating that without urgent action, cancer deaths could exceed 18 million by 2050 [3][4]. Group 1: Current State of Cancer Research - China has emerged as a key player in global cancer research, with a record number of studies presented at major international oncology conferences, including 60 studies at the ESMO Asia Congress 2025 and 73 at the ASCO annual meeting [3]. - The National Healthcare Security Administration has added 36 cancer drugs to the 2025 basic medical insurance catalog, representing 31.58% of the new additions, thereby expanding treatment options for cancer patients [3]. Group 2: Future Outlook on Cancer Management - Experts predict that within the next 25 years, cancer will be recognized as a controllable chronic disease, with significant advancements in theoretical and technological innovations required to achieve this goal [4][5]. - The global burden of cancer is expected to rise, with an estimated 28.4 million new cases by 2040, a 47% increase from 19.3 million in 2020 [6]. Group 3: Factors Influencing Cancer Development - Five main factors contributing to cancer development have been identified: external triggers, infection-related factors, hormonal/receptor abnormalities, lifestyle-related factors, and psychological and immune-related triggers [7]. - The essence of cancer is a disruption in the body's regulatory mechanisms, leading to uncontrolled cell proliferation, which emphasizes the need for strategies that enhance the body's regulatory capabilities [7]. Group 4: Innovations in Cancer Treatment - The integration of advanced technologies such as AI, genomics, and precision medicine is expected to improve cancer survival rates significantly [8]. - A new classification standard for cancer is anticipated to revolutionize management and treatment, promoting a collaborative approach across multiple disciplines [8]. Group 5: Challenges Ahead - The transition from fragmented to integrated treatment poses challenges, including the urgent need for knowledge updates among healthcare professionals and the development of innovative diagnostic and treatment technologies [10]. - Early diagnosis is crucial for improving treatment success rates, with AI playing a role in enhancing the identification of high-risk populations and optimizing screening processes [10]. Group 6: Immunotherapy as a Growth Area - Immunotherapy has emerged as a significant growth area in cancer treatment, with a projected compound annual growth rate of 177.4% from 2017 to 2023, potentially reaching a global market size of $84.9 billion by 2030 [11]. - Despite its early development stage, immunotherapy shows great promise, but challenges remain in biomarker selection, toxicity management, and cost control [11].

Group 1: Public Health Initiatives - Wuxi has initiated a comprehensive cancer prevention and control action, becoming the first city in the province to implement such a program, which includes cancer screening as a key project for three consecutive years [3] - A total of 1.1619 million residents have participated in cancer screenings, with 274,400 high-risk individuals assessed, leading to the diagnosis of 3,323 cases of precancerous lesions and "five cancers" [3] - The standardized cancer mortality rate in Wuxi has decreased from 95.34 per 100,000 in 2020 to 80.80 per 100,000 in 2024, significantly lower than the national average [3] Group 2: Elderly Care Services - Wuxi has 150 elderly care institutions with approximately 40,000 beds, over 80% of which are nursing beds, addressing the needs of the aging population [4] - The "Xixin Medical and Nursing" community home-based service initiative has been implemented, providing integrated medical and nursing services to the elderly [4] - The city has established 157 meal assistance centers and 709 community meal service facilities, with differentiated subsidies linked to service performance [4] Group 3: Employment and Economic Stability - Jiangyin City has maintained stable employment, with 18,200 new urban jobs created by the end of July this year [5] - Various measures have been taken to stabilize employment, including providing over 44,000 job opportunities and issuing 2.3 million yuan in entrepreneurial subsidies [5] - The city has established 66 talent recruitment stations and introduced 10,200 new college graduates into the workforce [5] Group 4: Urban Environment Improvement - Wuxi's urban management department has launched 1,319 special improvement projects across 151 areas, focusing on enhancing public spaces and facilities [6] - Initiatives include upgrading street scenery, waste collection systems, and public restrooms, aiming for significant improvements with minimal investment [6] - The city has supported the establishment of 432 seasonal fruit and vegetable stalls, enhancing local commerce while maintaining ecological aesthetics [6] Group 5: Education Resource Expansion - Wuxi has achieved a high school enrollment rate of 68.23% and is expanding educational resources through various initiatives [9] - New high school branches have been established, and transportation services have been improved with 117 customized bus routes for students [9] - The city is focused on promoting educational equity and quality through infrastructure development and resource allocation [9] Group 6: Cultural Enrichment - Wuxi is developing cultural facilities, including a new art museum and concert hall, with the art museum expected to open by the end of this year [10] - The city has hosted over 1,200 cultural events and is promoting grassroots cultural engagement through various programs [10] - The upcoming "Taihu Cultural Arts Season" will feature nearly 160 events, expected to benefit over one million residents [10]